Risk of mortality and cancer incidence in Barrett's esophagus - PubMed (original) (raw)
Risk of mortality and cancer incidence in Barrett's esophagus
Michael B Cook et al. Cancer Epidemiol Biomarkers Prev. 2007 Oct.
Abstract
Background: There are very few prospective follow-up studies of Barrett esophagus (BE) cohorts assessing the risk of extraesophageal cancer incidence or mortality. Such studies are necessary in order to understand the overall risks of cancer and death experienced by patients with BE.
Methods: A cohort of 502 patients with BE were identified at Leeds General Infirmary, England. Mortality and cancer incidence information were provided by the Office for National Statistics. Standardized mortality ratios (SMR) and standardized incidence ratios (SIR) were calculated using indirect standardization.
Results: All-cause mortality was found to be elevated in patients with BE [SMR, 1.21; 95% confidence interval (95% CI), 1.06, 1.37] and remained so after esophageal cancers were excluded (SMR, 1.16; 95% CI, 1.01-1.32). Increased mortality risks were also found for malignant neoplasms of the esophagus (SMR, 7.26; 95% CI, 3.87-12.42) and diseases of the digestive system (SMR, 2.03; 95% CI, 1.11-3.40). The remaining disease categories produced no altered risk estimates. Circulatory disease mortality was borderline statistically significant (SMR, 1.24; 95% CI, 1.00-1.52; P = 0.053) for those with a specialized intestinal metaplasia diagnosis of BE. In the cancer incidence analyses, esophageal malignancies (SIR, 8.66; 95% CI, 4.73-14.53) and esophageal adenocarcinomas (SIR, 14.29; 95% CI, 7.13-22.56) were found to be increased in BE. All remaining analyses provided unaltered risks, including that of colorectal cancer.
Conclusions: This study has shown evidence of an increased risk of esophageal cancer incidence and mortality in BE. It has also shown that those who have a histologic BE diagnosis may also have an increased risk of circulatory disease mortality.
Similar articles
- Total cancer incidence and overall mortality are not increased among patients with Barrett's esophagus.
Schouten LJ, Steevens J, Huysentruyt CJ, Coffeng CE, Keulemans YC, van Leeuwen FE, Driessen AL, van den Brandt PA. Schouten LJ, et al. Clin Gastroenterol Hepatol. 2011 Sep;9(9):754-61. doi: 10.1016/j.cgh.2011.04.008. Epub 2011 Apr 15. Clin Gastroenterol Hepatol. 2011. PMID: 21570484 - Surveillance in Barrett's oesophagus: will a strategy focused on a high-risk group reduce mortality from oesophageal adenocarcinoma?
Quera R, O'Sullivan K, Quigley EM. Quera R, et al. Endoscopy. 2006 Feb;38(2):162-9. doi: 10.1055/s-2005-921184. Endoscopy. 2006. PMID: 16479424 - Mortality in Barrett's esophagus: three decades of experience at a single center.
Caygill CP, Royston C, Charlett A, Wall CM, Gatenby PA, Ramus JR, Watson A, Winslet M, Bardhan KD. Caygill CP, et al. Endoscopy. 2012 Oct;44(10):892-8. doi: 10.1055/s-0032-1309842. Epub 2012 Jul 2. Endoscopy. 2012. PMID: 22752886 - Diagnosis and recognition of early esophageal neoplasia.
Herszényi L, Pregun I, Tulassay Z. Herszényi L, et al. Dig Dis. 2009;27(1):24-30. doi: 10.1159/000210100. Epub 2009 May 8. Dig Dis. 2009. PMID: 19439957 Review. - Surgical therapy for Barrett's esophagus with high-grade dysplasia and early esophageal carcinoma.
Gilbert S, Jobe BA. Gilbert S, et al. Surg Oncol Clin N Am. 2009 Jul;18(3):523-31. doi: 10.1016/j.soc.2009.03.008. Surg Oncol Clin N Am. 2009. PMID: 19500741 Review.
Cited by
- Diagnosis and management of Barrett's oesophagus.
Jankowski J, Barr H, Wang K, Delaney B. Jankowski J, et al. BMJ. 2010 Sep 10;341:c4551. doi: 10.1136/bmj.c4551. BMJ. 2010. PMID: 20833742 Free PMC article. Review. No abstract available. - Barrett esophagus and life expectancy: implications for screening?
Kuipers EJ. Kuipers EJ. Gastroenterol Hepatol (N Y). 2011 Oct;7(10):689-91. Gastroenterol Hepatol (N Y). 2011. PMID: 22298963 Free PMC article. No abstract available. - Cdx1 and c-Myc foster the initiation of transdifferentiation of the normal esophageal squamous epithelium toward Barrett's esophagus.
Stairs DB, Nakagawa H, Klein-Szanto A, Mitchell SD, Silberg DG, Tobias JW, Lynch JP, Rustgi AK. Stairs DB, et al. PLoS One. 2008;3(10):e3534. doi: 10.1371/journal.pone.0003534. Epub 2008 Oct 27. PLoS One. 2008. PMID: 18953412 Free PMC article. - Magnitude of Missed Esophageal Adenocarcinoma After Barrett's Esophagus Diagnosis: A Systematic Review and Meta-analysis.
Visrodia K, Singh S, Krishnamoorthi R, Ahlquist DA, Wang KK, Iyer PG, Katzka DA. Visrodia K, et al. Gastroenterology. 2016 Mar;150(3):599-607.e7; quiz e14-5. doi: 10.1053/j.gastro.2015.11.040. Epub 2015 Nov 24. Gastroenterology. 2016. PMID: 26619962 Free PMC article. - CYR61 and TAZ Upregulation and Focal Epithelial to Mesenchymal Transition May Be Early Predictors of Barrett's Esophagus Malignant Progression.
Cardoso J, Mesquita M, Dias Pereira A, Bettencourt-Dias M, Chaves P, Pereira-Leal JB. Cardoso J, et al. PLoS One. 2016 Sep 1;11(9):e0161967. doi: 10.1371/journal.pone.0161967. eCollection 2016. PLoS One. 2016. PMID: 27583562 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical